![]() ![]() She has significant healthcare, operations, and global business expertise – with more than three decades of experience in leadership positions at Johnson & Johnson. She is also a member of the company’s Executive Committee. Kathryn Wengel is Executive Vice President, Chief Technical Operations & Risk Officer for Johnson & Johnson. Title: EVP, Chief Technical Operation & Risk Officer This is achieved through our dedicated and resourceful people in addition to our work practices and the use of innovative technologies, which drive positive outcomes for our customers.” We do this by delivering industry-leading solutions and best-in-class performance in clinical development. “At ICON, we work to improve the lives of patients by accelerating the development of our customers’ drugs and devices. ![]() He also holds an MBA from the University of Birmingham (UK). Prior to joining Quintiles, Cutler worked with Sandoz (now Novartis) in Australia and Europe. These include Chief Executive Officer of Kendle, Senior Vice President, Global Project Management at Quintiles (now IQVIA) and Senior Vice President, Clinical, Medical and Regulatory, also at Quintiles. Throughout his career in the clinical research and pharmaceutical industries, Cutler has held numerous senior leadership positions. With headquarters in Dublin, Ireland, ICON employs approximately 41,150 employees in 53 countries. From molecule to medicine, the company advances clinical research by providing outsourced services to pharmaceutical, biotechnology, medical device, and government and public health organizations. Notably, ICON is the world’s leading clinical research organization. As CEO, Cutler has overseen a period of significant progress for ICON, driven by both strong organic growth and a number of strategic acquisitions, including PRA Health Sciences in 2021. Cutler joined ICON as Group President, Clinical Research Services in 2011–and has been a member of the board since November 2015. Steve Cutler was appointed Chief Executive Officer of ICON in March 2017, having previously served as Chief Operating Officer for three years. Please join us in celebrating The Top 25 Healthcare Technology Leaders of New Jersey for 2023. Today, he serves as the Vice President of Clinical Sciences at Cognivue, which provides the world's first FDA-cleared computerized test of cognitive function. Lastly, Douglas Beck, is among the most prolific authors in audiology with more than 208 publications. launch of the multi-billion dollar drug, Otezla. Meanwhile, Sheri Lydick is leading BioAtla as its Chief Commercial Officer, having previously worked at numerous top healthcare companies–and notably spearheaded the U.S. With more than 25 years of experience in the global biopharmaceutical industry, Handa has generated multi-billion dollars' worth of value through strategic alliances, licensing, M&A, and commercialization of new ventures. In recognition of the state's many achievements, this year's list honors some of the most influential thought leaders within New Jersey's booming healthcare technology industry.Īn excellent example of an outstanding healthcare technology leader is Pavan Handa, the SVP of Strategic Portfolio Management for Amneal Pharmaceuticals. This is bolstered by New Jersey's 42 teaching hospitals and 5 medical schools that are preparing the medical practitioners and researchers of the future. In fact, the healthcare industry plays a vital role in the prosperity of the Garden State's economic well-being, contributing $37 billion to the state's economy each year. Home to more than 22,645 healthcare establishments, New Jersey is a hotbed for cutting-edge research and treatment in the medical and life sciences fields. iScience 25:104136 (2022).The Healthcare Technology Report is pleased to announce The Top 25 Healthcare Technology Leaders of New Jersey for 2023. Identified human breast milk compositions effectively inhibit SARS-CoV-2 and variants infection and replication. Detection of SARS-CoV-2 Antigens in the AV-Node of a Cardiac Conduction System-A Case Report. ![]() Anti-SARS-CoV-2 equine F (Ab')2 immunoglobulin as a possible therapy for COVID-19. Detection of Sars-Cov-2 antigens in thyroid gland showing histopathological features of subacute thyroiditis. Optimization, Production, Purification and Characterization of HIV-1 GAG-Based Virus-like Particles Functionalized with SARS-CoV-2. Publishing research using ab272504? Please let us know so that we can cite the reference in this datasheet.Īb272504 has been referenced in 34 publications. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |